ArticleFrontiers in pharmacology2025
Serum metabolomics identifies novel prognostic biomarkers in
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: 33 patients with Results: Significant differences were observed between the survival and death groups in clinical manifestations-such as gastrointestinal bleeding, dizziness, headache, delirious coma, infection, and shortness of breath-and in biochemical indicators, including alanine transaminase (ALT), aspartate transaminase (AST), prothrombin time and activated partial thromboplastin time (APTT). Metabolomic analysis identified 80 differentially expressed metabolites involved primarily in amino acid and unsaturated fatty acid metabolism. ROC analysis (AUC >0.9) screened nine potential metabolic biomarkers for predicting clinical outcomes: 9,10-Epoxyoctadecenoic acid, Phosphatidylinositol(16:0/18:2 (9Z,12Z)), N-Acetyl-L-aspartic acid, PI(20:3 (5Z,8Z,11Z)/18:0), Propionylcarnitine, Proline betaine, 4'-Methyl-(-)-epigallocatechin 3-(4-methyl-gallate), PG (18:1 (11Z)/22:6 (4Z,7Z,10Z,13Z,16Z,19Z)), and L-Proline. Notably, correlation analysis revealed that 9,10-Epoxyoctadecenoic acid was positively correlated with AST and activated partial thromboplastin time, whereas 4'-Methyl-(-)-epigallocatechin 3-(4-methyl-gallate), N-acetyl-L-aspartic acid, PI(16:0/18:2 (9Z,12Z)), PI(20:3 (5Z,8Z,11Z)/18:0), and Propionylcarnitine showed negative correlations with various liver and coagulation parameters. Conclusion: Serum metabolomics has identified metabolic biomarkers capable of predicting mortality in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.